Alexis Borisy, IDRx co-founder

New biotech from Alex­is Borisy will test Mer­ck KGaA, Blue­print can­cer drug com­bo in bid to ful­fill Gleevec promise

Alex­is Borisy and Ben Aus­pitz want to be in­tel­li­gent with their lat­est biotech, not “stu­pid.”

That’s in the words of Borisy, the re­peat biotech en­tre­pre­neur be­hind the likes of Blue­print Med­i­cines and EQRx. He and busi­ness part­ner Aus­pitz, a long-time in­dus­try in­vestor at F-Prime Cap­i­tal, want to bring to­geth­er “in­tel­li­gent­ly de­signed” can­cer drugs, hence their start­up’s name: IDRx.

In launch­ing their lat­est biotech, with a $122 mil­lion Se­ries A, the duo be­lieves it’s brought to­geth­er two drugs that can be “best in class” as a com­bi­na­tion ther­a­py for cer­tain can­cers. At the heart of their new com­pa­ny is an old ven­ture: Blue­print. IDRx has se­cured the li­cense to a Blue­print as­set and a Mer­ck KGaA as­set, with both com­pa­nies re­tain­ing eq­ui­ty stakes in the start­up in ex­change for the trans­fer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.